DrugPatentWatch Database Preview
NPLATE Drug Profile
Email this page to a colleague
» See Plans and PricingSummary for Tradename: NPLATE
| Patents: | 22 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for NPLATE |
Recent Clinical Trials for NPLATE
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 |
| Amgen | Phase 3 |
| University Children's Hospital Basel | Phase 4 |
Pharmacology for NPLATE
| Mechanism of Action | Thrombopoietin Receptor Agonists |
| Physiological Effect | Increased Megakaryocyte Maturation Increased Platelet Production |
Company Disclosures: US Patents for NPLATE
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2018-10-23 | RX | Orphan | company |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2018-10-23 | RX | Orphan | company |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2018-10-23 | RX | Orphan | company |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2018-10-23 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for NPLATE
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | Orphan | search |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | AMGEN INC. (Thousand Oaks, CA) | 2039-02-26 | RX | Orphan | search |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) | 2031-04-05 | RX | Orphan | search |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | CORNELL UNIVERSITY (Ithaca, NY) | 2035-10-02 | RX | Orphan | search |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | AMGEN INC. (Thousand Oaks, CA) | 2039-12-21 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for NPLATE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1107881 | Start Trial |
| China | 1250721 | Start Trial |
| China | 1325447 | Start Trial |
| Germany | 69934425 | Start Trial |
| Taiwan | I257394 | Start Trial |
| Portugal | 2319928 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NPLATE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 91598 | Luxembourg | Start Trial | PRODUCT NAME: ROMIPLOSTIM (NPLATE - ROMIPLOSTIM) |
| PA2009006,C1124961 | Lithuania | Start Trial | PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| C 2009 009 | Romania | Start Trial | PRODUCT NAME: NPLATE-ROMIPLOSTIM; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/497/001, RO EU/1/08/497/002; DATE OF NATIONAL AUTHORISATION: 20090204; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/08/497/001, EMEA EU/1/08/497/002; DATE OF FIRST AUTHORISATION IN EEA: 20090204 |
| PA2009006 | Lithuania | Start Trial | PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| C01124961/01 | Switzerland | Start Trial | FORMER REPRESENTATIVE: BOHEST AG, CH |
| 346 | Finland | Start Trial | |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
